-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the continuous expansion of the pharmaceutical market, the increasing competition among pharmaceutical companies, the growing need to expand product lines to maintain profitability, and the influx of a large amount of new capital, the trend of cooperation and mergers and acquisitions in the pharmaceutical field is intensifying
.
Among them, especially large multinational pharmaceutical companies, due to their strong strength, in order to cope with the problems of the imminent expiration of the original research drugs and the patent cliff, in recent years, the "buy, buy, buy" model has been launched
.
At present, less than two weeks into 2022, a number of multinational pharmaceutical companies have issued cooperation announcements
.
Recently, Absci announced a research collaboration with Merck &
Co.
The companies will utilize Absci's AI-powered Integrated Drug Creation platform for drug development
.
According to the agreement, Merck can select up to three targets and enter into a drug discovery collaboration agreement, and Absci will be eligible to receive up to $610 million in up-front and milestone payments for all three targets, as well as research funding and tiered sales royalties
.
Coincidentally, on the same day, two pharmaceutical companies also announced that they had reached a new cooperation agreement
.
Among them, Neurimmune AG announced that it has signed an exclusive global collaboration and license agreement with Alexion, a rare disease group under AstraZeneca, to develop an investigational fully human monoclonal antibody NI006 against misfolded transthyretin
.
It is reported that NI006 is used for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
.
The total transaction value of the transaction will be as high as $760 million, including an upfront payment of $30 million
.
Separately, Sanofi announced a research collaboration licensing agreement with Exscientia
.
Will co-develop up to 15 novel small molecule drug candidates in oncology and immunology through an end-to-end artificial intelligence (AI)-driven personalized medicine platform developed by Exscientia
.
Under the partnership agreement, Exscientia will receive an upfront payment of $100 million from Sanofi, future research, translational, clinical development, regulatory and commercial milestone payments totaling up to $5.
2 billion, as well as tiered royalties on future product sales
.
In addition to the above-mentioned companies, Lilly, Alnylam, TRexBio, and Amgen have all released announcements of cooperation with other companies before this
.
In this regard, analysts believe that the current competition in the pharmaceutical industry is already very fierce.
In order to increase the scale of the industry, reduce homogeneous competition, and expand the enterprise, pharmaceutical companies will continue to enrich the product pipeline and improve the research and development strength of innovative drugs
.
In this context, pharmaceutical companies frequently initiate cooperation and acquisitions will also become the general trend
.
Through mergers and acquisitions, multinational pharmaceutical companies can acquire the blockbuster products of the acquired company and enrich the product pipeline; at the same time, they can also obtain the technology of the acquired company in drug research and development, improve the status of multinational pharmaceutical companies in this field; and promote the research and development of new products progress
.
Therefore, according to the current status of the industry, the industry expects that in 2022, with the continuous transformation of the global pharmaceutical industry, competition will continue to intensify, and multinational pharmaceutical companies will continue to accelerate acquisitions in order to maintain their competitiveness
.
It is worth noting that in recent years, domestic innovative companies have attracted more and more attention from large multinational pharmaceutical companies, and the cooperation between Chinese and foreign pharmaceutical companies will also be worth looking forward to in the future
.
.
Among them, especially large multinational pharmaceutical companies, due to their strong strength, in order to cope with the problems of the imminent expiration of the original research drugs and the patent cliff, in recent years, the "buy, buy, buy" model has been launched
.
At present, less than two weeks into 2022, a number of multinational pharmaceutical companies have issued cooperation announcements
.
Recently, Absci announced a research collaboration with Merck &
Co.
The companies will utilize Absci's AI-powered Integrated Drug Creation platform for drug development
.
According to the agreement, Merck can select up to three targets and enter into a drug discovery collaboration agreement, and Absci will be eligible to receive up to $610 million in up-front and milestone payments for all three targets, as well as research funding and tiered sales royalties
.
Coincidentally, on the same day, two pharmaceutical companies also announced that they had reached a new cooperation agreement
.
Among them, Neurimmune AG announced that it has signed an exclusive global collaboration and license agreement with Alexion, a rare disease group under AstraZeneca, to develop an investigational fully human monoclonal antibody NI006 against misfolded transthyretin
.
It is reported that NI006 is used for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
.
The total transaction value of the transaction will be as high as $760 million, including an upfront payment of $30 million
.
Separately, Sanofi announced a research collaboration licensing agreement with Exscientia
.
Will co-develop up to 15 novel small molecule drug candidates in oncology and immunology through an end-to-end artificial intelligence (AI)-driven personalized medicine platform developed by Exscientia
.
Under the partnership agreement, Exscientia will receive an upfront payment of $100 million from Sanofi, future research, translational, clinical development, regulatory and commercial milestone payments totaling up to $5.
2 billion, as well as tiered royalties on future product sales
.
In addition to the above-mentioned companies, Lilly, Alnylam, TRexBio, and Amgen have all released announcements of cooperation with other companies before this
.
In this regard, analysts believe that the current competition in the pharmaceutical industry is already very fierce.
In order to increase the scale of the industry, reduce homogeneous competition, and expand the enterprise, pharmaceutical companies will continue to enrich the product pipeline and improve the research and development strength of innovative drugs
.
In this context, pharmaceutical companies frequently initiate cooperation and acquisitions will also become the general trend
.
Through mergers and acquisitions, multinational pharmaceutical companies can acquire the blockbuster products of the acquired company and enrich the product pipeline; at the same time, they can also obtain the technology of the acquired company in drug research and development, improve the status of multinational pharmaceutical companies in this field; and promote the research and development of new products progress
.
Therefore, according to the current status of the industry, the industry expects that in 2022, with the continuous transformation of the global pharmaceutical industry, competition will continue to intensify, and multinational pharmaceutical companies will continue to accelerate acquisitions in order to maintain their competitiveness
.
It is worth noting that in recent years, domestic innovative companies have attracted more and more attention from large multinational pharmaceutical companies, and the cooperation between Chinese and foreign pharmaceutical companies will also be worth looking forward to in the future
.
